A Pilot Study of the Safety and Efficacy of Escalating Doses of ON 01910.Na in Patients With Relapsed Mantle Cell Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia, and Related Lymphoid Malignancies
Mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), multiple myeloma (MM) and
the related lymphoid malignancies included in this protocol are all incurable lymphoid
malignancies that mainly affect persons in their late 60s and early 70s. Conventional
chemotherapy can be effective at achieving high rates of clinical response, but relapse
following these responses is almost universal. Response rates in the relapsed setting are
inferior due to acquired resistance of the tumor cells, and new therapies with novel
mechanisms of action are needed. Our aim in this study is to specifically address the needs
of these patients for whom few effective treatments are available.
Patients with lymphoid malignancies relapse due to acquired resistance of tumor cells to
chemotherapy agents and innovative targeted therapies which overcome these mechanisms of
resistance are needed. One such investigational drug, ON 01910.Na, is a potent and
selective inhibitor of the cell cycle and leads to reduction in cyclin D1 expression. In
vitro, ON01910.Na shows activity against CLL and MCL cell lines with resultant cellular
death. The overexpression of cyclin D1 in these related lymphoid malignancies provides a
rationale for its use in selected patients with these conditions.
We therefore propose this non-randomized, pilot, dose-escalating Phase I study of ON
01910.Na in patients with MCL, CLL, MM and related lymphoid malignancies who have relapsed
after or are refractory to standard therapy.
The primary objective is to determine the toxicity profile (including the maximum tolerated
dose and recommended phase II dose) of ON 01910.Na when administered the first 2 (or
amended later to 3) days of a 2-week cycle in escalating doses in patients with MCL, CLL,
MM and related lymphoid malignancies.
The first cohort was dosed at 1200mg/m2/day times 2 days. The second cohort was dosed at
1500mg/m2/day for 2 days. Three subjects were enrolled into the third cohort at
1800mg/m2/day times 2 days. One subject completed the 1800mg/m2/ day times 2 days dosing
scheme. Two subjects stopped study drug after the first dose due to progressive disease.
The 3 subjects who received 1800mg/m2/day times 2 days will compose cohort 3. New safety
data from the drug manufacturer lead to Amendment L, which changed the dosing from 48 hours
to 72 hours. On November 18, 2010, the IRB approved Amendment L, which changed the dosing
for the new cohorts 4 and 5 to 1800mg/day times 3 days, and 2100mg/day times 3 days,
Secondary objectives include, the biological effects of ON 01910.Na (for example cyclin D1
expression) on cell-cycle pathways of cells obtained from blood, lymph nodes or bone marrow,
the toxicity profile of ON 01910.Na with subsequent dosing after 2 cycles of therapy, early
indications of biologic activity after 4 cycles of therapy, evaluation of the
pharmacokinetics of ON 01910.Na at the RPTD level, and indications of biologic activity
during extended access (after 4 cycles (day 56)).
The primary endpoint will be the toxicity profile at each dose level through day 28 (cycle 2
Secondary endpoints include the reduction in lymph nodes, quantification of circulating
lymphoma cells, assessment of extranodal disease sites, and/or measurement of the malignant
monoclonal proteins in the serum or urine after 4 cycles of therapy (day 56).
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Safety of escalating doses ON01910.Na at day 28.
Mark J Roschewski, M.D.
National Cancer Institute (NCI)
United States: Federal Government
|National Institutes of Health Clinical Center, 9000 Rockville Pike||Bethesda, Maryland 20892|